^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
Published date:
01/10/2018
Excerpt:
Thirty-six patients received treatment with trastuzumab plus pertuzumab for tumors with HER2 mutations (without amplification/overexpression); four of these patients (11%; 95% CI, 3% to 26%) had objective responses...Fourteen of the 36 patients with HER2-mutated tumors had NSCLC (adenocarcinoma, n = 13; adenosquamous, n = 1); in this group, three patients (21%; 95% CI, 5% to 51%) had PR and three had SD > 120 days.
DOI:
10.1200/JCO.2017.75.3780
Trial ID:
